Sage Therapeutics, Inc. (SAGE)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 13.10 |
| Open | 13.50 |
| Bid | 13.92 x 800 |
| Ask | 13.98 x 800 |
| Day's range | 13.45 - 13.97 |
| 52-week range | 10.92 - 59.99 |
| Volume | |
| Avg. volume | 1,066,479 |
| Market cap | 838.937M |
| Beta (5Y monthly) | 0.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.39 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 21.88 |
Insider MonkeySage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript April 25, 2024 Sage Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.8 EPS, expectations were $-1.63. Sage Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
Simply Wall St.Earnings Update: Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Are Boosting Their Estimates
Investors in Sage Therapeutics, Inc. ( NASDAQ:SAGE ) had a good week, as its shares rose 2.7% to close at US$13.69...
ZacksSage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
© 2024 Yahoo. All rights reserved.